News
Sarepta Therapeutics Stock Plunges After Another Patient Death Is Linked to One of Its Gene Therapies
One of biotech’s highest fliers, Sarepta Therapeutics, lost more than a third of its market value on Friday after executives said that one of its experimental gene-replacement therapies was linked to the death of a 51-year-old man last month who received the treatment in a clinical trial.
On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.
Asianet Newsable on MSN1d
Sarepta Draws Wall Street Ire After Third Patient Death This Year: Analyst Says ‘Deeply Concerning’ The Incident Wasn’t Reported EarlierA company spokesperson told Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage ...
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
Across the recent three months, 26 analysts have shared their insights on Sarepta Therapeutics (NASDAQ: SRPT), expressing a variety of opinions spanning from bullish to bearish. The table below ...
Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...
The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback